Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

被引：201

作者：

Bikdeli, Behnood ^{[1
,2
,3
]}

Madhavan, Mahesh V. ^{[3
]}

Gupta, Aakriti ^{[1
,2
,3
]}

Jimenez, David ^{[4
,5
]}

Burton, John R. ^{[1
]}

Nigoghossian, Caroline Der ^{[1
]}

Chuich, Taylor ^{[1
]}

Nouri, Shayan Nabavi ^{[1
]}

Dreyfus, Isaac ^{[1
]}

Driggin, Elissa ^{[1
]}

Sethi, Sanjum ^{[1
]}

Sehgal, Kartik ^{[6
,7
]}

Chatterjee, Saurav ^{[8
]}

Ageno, Walter ^{[9
]}

Madjid, Mohammad ^{[10
]}

Guo, Yutao ^{[11
,12
,13
]}

Tang, Liang V. ^{[14
]}

Hu, Yu ^{[14
]}

Bertoletti, Laurent ^{[15
,16
]}

Giri, Jay ^{[17
,18
,19
]}

Cushman, Mary ^{[20
]}

Quere, Isabelle ^{[21
]}

Dimakakos, Evangelos P. ^{[22
]}

Gibson, C. Michael ^{[6
,7
]}

Lippi, Giuseppe ^{[23
]}

Favaloro, Emmanuel J. ^{[24
,25
]}

Fareed, Jawed ^{[26
]}

Tafur, Alfonso J. ^{[27
,28
,30
]}

Francese, Dominic P.

Batra, Jaya

Falanga, Anna ^{[29
]}

Clerkin, Kevin J. ^{[1
]}

Uriel, Nir ^{[1
]}

Kirtane, Ajay ^{[1
,2
]}

McLintock, Claire ^{[30
]}

Hunt, Beverley J. ^{[31
]}

Spyropoulos, Alex C. ^{[30
]}

Barnes, Geoffrey D. ^{[31
,32
]}

Eikelboom, John W. ^{[33
]}

Weinberg, Ido ^{[34
]}

Schulman, Sam ^{[35
,36
,37
]}

Carrier, Marc ^{[38
]}

Piazza, Gregory ^{[39
]}

Beckman, Joshua A. ^{[40
]}

Leon, Martin B. ^{[1
,3
]}

Stone, Gregg W. ^{[41
,42
]}

Rosenkranz, Stephan ^{[43
,44
]}

Goldhaber, Samuel Z. ^{[6
]}

Parikh, Sahil A. ^{[1
,3
]}

Monreal, Manuel ^{[45
]}

机构：

[1] Columbia Univ, Irving Med Ctr, New York Presbyterian Hosp, New York, NY 10027 USA

[2] Yale Sch Med, Ctr Outcomes Res & Evaluat CORE, New Haven, CT 06510 USA

[3] Cardiovasc Res Fdn, Clin Trials Ctr, New York, NY 10019 USA

[4] Hosp Ramon & Cajal, Resp Dept, Madrid, Spain

[5] Univ Alcala IRYCIS, Dept Med, CIBER Enfermedades Resp CIBERES, Madrid, Spain

[6] Harvard Med Sch, Boston, MA 02115 USA

[7] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[8] North Shore & Long Isl Jewish Univ Hosp, New York, NY USA

[9] Univ Insubria, Dept Med & Surg, Varese, Italy

[10] Univ Texas Hlth Sci Ctr, McGovern Med Sch, Houston, TX USA

[11] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China

[12] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, Liverpool, Merseyside, England

[13] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England

[14] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Inst Hematol, Wuhan, Peoples R China

[15] Univ Jean Monnet, Dept Med Vasc & Therapeut, CIC 1408, INNOVTE,CHU St Etienne, St Etienne, France

[16] Univ Jean Monnet, INSERM UMR1059, St Etienne, France

[17] Hosp Univ Penn, Cardiovasc Div, 3400 Spruce St, Philadelphia, PA 19104 USA

[18] Univ Penn, Leonard Davis Inst Hlth Econ, Penn Cardiovasc Outcomes Qual & Evaluat Res Ctr, Philadelphia, PA 19104 USA

[19] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA

[20] Univ Vermont, Coll Med, Burlington, VT USA

[21] Univ Montpellier, Dept Vasc Med, CHU Montpellier, InnoVTE F CRIN Network, Montpellier, France

[22] Athens Sch Med, Sotiria Gen Hosp, Oncol Unit GPP, Athens, Greece

[23] Univ Hosp Verona, Lab Clin Chem & Hematol, Verona, Italy

[24] Westmead Hosp, NSW Hlth Pathol, Lab Haematol, Inst Clin Pathol & Med Res ICPMR, Westmead, NSW, Australia

[25] Sydney Ctr Thrombosis & Haemostasis, Westmead, NSW, Australia

[26] Loyola Univ Med Ctr, Chicago, IL USA

[27] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA

[28] NorthShore Univ HealthSyst, Dept Med, Div Vasc Med, Skokie, IL USA

[29] Univ Milano Bicocca, Hosp Papa Giovanni XXIII, Dept Immunohematol & Transfus Med, Bergamo, Italy

[30] Auckland City Hosp, Auckland, New Zealand

[31] St Thomas Hosp, London, England

[32] Donald & Barbara Zucker Sch Med Hofstra Northwell, New York, NY USA

[33] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA

[34] Univ Michigan, Frankel Cardiovasc Ctr, Ann Arbor, MI 48109 USA

[35] McMaster Univ & Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada

[36] Massachusetts Gen Hosp, Boston, MA 02114 USA

[37] IM Sechenov First Moscow State Med Univ, Dept Obstet & Gynecol, Moscow, Russia

[38] McMaster Univ, Hamilton, ON, Canada

[39] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

[40] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[41] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[42] Vanderbilt Univ, Sch Med, Nashville, TN USA

[43] Icahn Sch Med Mt Sinai, Zena & Michael Wiener Cardiovasc Inst, New York, NY USA

[44] Univ Cologne, Ctr Heart, Dept Cardiol, Cologne Cardiovasc Res Ctr CCRC, Cologne, Germany

[45] Univ Catolica Murcia, Hosp Univ Germans Trials & Pujol, Dept Internal Med, Barcelona, Spain

[46] Yale Sch Publ Hlth, Dept Hlth Policy & Adm, New Haven, CT USA

[47] Yale Sch Med, Sect Cardiovasc Med, Dept Internal Med, New Haven, CT USA

[48] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany

[49] Aalborg Univ, Dept Clin Med, Aalborg Thrombosis Res Unit, Aalborg, Denmark

来源：

THROMBOSIS AND HAEMOSTASIS | 2020年 / 120卷 / 07期

关键词：

coronavirus disease 2019; thrombosis; inflammation; fibrinolytic therapy; anticoagulation; immunomodulator; antithrombin; thrombomodulin; RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL PATIENTS; DISSEMINATED INTRAVASCULAR COAGULATION; HEPARIN-INDUCED THROMBOCYTOPENIA; ACUTE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; NEW-YORK-CITY; ANTITHROMBIN-III; INTRACRANIAL HEMORRHAGE; PULMONARY COAGULOPATHY;

D O I：

10.1055/s-0040-1713152

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.

引用

页码：1004 / 1024

页数：21

共 191 条

[1]

RE: ISTH interim guidance to recognition and management of coagulopathy in COVID-19 [J].

Akima, Satoshi ;

McLintock, Claire ;

Hunt, Beverley J. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (08) :2057-2058

[2]

Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description [J].

Al-Abdallat, Mohammad Mousa ;

Payne, Daniel C. ;

Alqasrawi, Sultan ;

Rha, Brian ;

Tohme, Rania A. ;

Abedi, Glen R. ;

Al Nsour, Mohannad ;

Iblan, Ibrahim ;

Jarour, Najwa ;

Farag, Noha H. ;

Haddadin, Aktham ;

Al-Sanouri, Tarek ;

Tamin, Azaibi ;

Harcourt, Jennifer L. ;

Kuhar, David T. ;

Swerdlow, David L. ;

Erdman, Dean D. ;

Pallansch, Mark A. ;

Haynes, Lia M. ;

Gerber, Susan I. .

CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) :1225-1233

[3]

Antithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis [J].

Allingstrup, Mikkel ;

Wetterslev, Jorn ;

Ravn, Frederikke B. ;

Moller, Ann Merete ;

Afshari, Arash .

INTENSIVE CARE MEDICINE, 2016, 42 (04) :505-520

[4]

[Anonymous], 2020, GENENTECHS ARTHRITIS

[5]

[Anonymous], 2020, JAMA-J AM MED ASSOC, DOI DOI 10.1001/JAMA.2020.6775

[6]

[Anonymous], Lancet, DOI DOI 10.1016/S0140-6736(20)30567-5

[7]

[Anonymous], THERAPEUTIC EFFECTS

[8]

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome [J].

Arabi, Yaseen M. ;

Mandourah, Yasser ;

Al-Hameed, Fahad ;

Sindi, Anees A. ;

Almekhlafi, Ghaleb A. ;

Hussein, Mohamed A. ;

Jose, Jesna ;

Pinto, Ruxandra ;

Al-Omari, Awad ;

Kharaba, Ayman ;

Almotairi, Abdullah ;

Al Khatib, Kasim ;

Alraddadi, Basem ;

Shalhoub, Sarah ;

Abdulmomen, Ahmed ;

Qushmaq, Ismael ;

Mady, Ahmed ;

Solaiman, Othman ;

Al-Aithan, Abdulsalam M. ;

Al-Raddadi, Rajaa ;

Ragab, Ahmed ;

Balkhy, Hanan H. ;

Al Harthy, Abdulrahman ;

Deeb, Ahmad M. ;

Al Mutairi, Hanan ;

Al-Dawood, Abdulaziz ;

Merson, Laura ;

Hayden, Frederick G. ;

Fowler, Robert A. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197 (06) :757-767

[9]

Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor [J].

Aungraheeta, Riyaad ;

Conibear, Alexandra ;

Butler, Mark ;

Kelly, Eamonn ;

Nylander, Sven ;

Mumford, Andrew ;

Mundell, Stuart J. .

BLOOD, 2016, 128 (23) :2717-2728

[10]

Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting About Vorapaxar [J].

Baker, Nevin C. ;

Lipinski, Michael J. ;

Lhermusier, Thibault ;

Waksman, Ron .

CIRCULATION, 2014, 130 (15) :1287-1294

← 1 2 3 4 5 6 7 8 9 10 →